Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib DPI in Idiopathic Pulmonary Fibrosis (INFLO-2)
NCT07679893Phase 2Recruiting
- Sponsor
- MannKind
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib dry powder inhaler in idiopathic pulmonary fibrosis (IPF), sponsored by MannKind. Started May 2026; status: recruiting.
02
Drugs
nintedanib dry powder inhaler
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07679893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679893.